Navigation Links
China Chemical Pharmaceutical Industry Report, 2013-2016
Date:12/13/2014

DUBLIN, Dec. 11, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/5ft7zn/china_chemical) has announced the addition of the "China Chemical Pharmaceutical Industry Report, 2013-2016" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and and China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.

China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.

Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.

North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies' total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.

Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies' development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.

Key Topics Covered:

1. Overview of Chemical Pharmaceutical Industry

2. Development of Global Chemical Pharmaceutical Industry

3. Development of China Chemical Pharmaceutical Industry

4. China Chemical Pharmaceutical Market Segments

5. Key Chinese Chemical APIs Manufacturers

6. Key Chinese Chemical Preparation Manufacturers

7. Conclusion and Forecast

Companies Mentioned:

  • China Resources Double-Crane Pharmaceutical Co., Ltd.
  • Hainan Haiyao Co., Ltd.
  • Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
  • Huaren Pharmaceutical Co., Ltd.
  • Humanwell Healthcare (Group) Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • North China Pharmaceutical Co., Ltd.
  • Northeast Pharmaceutical Group Co., Ltd.
  • Shandong Xinhua Pharmaceutical Company Limited
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Shenzhen Hepalink Pharmaceutical Co., Ltd.
  • Tianjin Tianyao Pharmaceuticals Co., Ltd.
  • Xizang Haisco Pharmaceutical Group Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Zhejiang Medicine Co., Ltd.
  • Zhejiang NHU Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/5ft7zn/china_chemical

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. China Jo-Jo Drugstores Sales Reimbursed by Health Insurance Companies Increased 260% and 50% respectively for Online and Offline Pharmacy
2. China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer
3. China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results
4. China Recombinant Protein Drug Industry Report, 2014-2017
5. Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition)
6. CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma
7. Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2012-2018
8. China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2014
9. China Nepstar Chain Drugstore to Report Third Quarter 2014 Financial Results on November 26, 2014
10. China Biologic to Build Two New Plasma Collection Stations in Hebei Province
11. China Biologic to Report Third Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2020)... YORK (PRWEB) , ... February 14, 2020 , ... ... a cutting-edge dental practice that conveniently offers a complete range of dental services under ... 2019 Top Patient Rated Dentist by Find Local Doctors . Find Local Doctors ...
(Date:2/13/2020)... ... February 13, 2020 , ... ... to announce that Lee Ann Gee, MD, is joining our team starting February ... expert in medication management, cognitive behavioral therapy, and psychodynamic therapy. Her extensive medical ...
(Date:2/13/2020)... ... February 13, 2020 , ... Data released today by United ... of Health (NIH) in 2019 had a significant economic impact across the United States, ... annual report, “ NIH’s Role in Sustaining the U.S. Economy ,” found that in ...
Breaking Medicine Technology:
(Date:2/20/2020)... ... February 20, 2020 , ... R3 Stem Cell, the nation's ... to complete 70 complimentary stem cell procedures on military veterans in 2019. ... no cost. , At the R3 Stem Cell Training Course for doctors , providers ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American College of Lifestyle ... Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable and ... Driven by resident involvement, the curriculum has included residents in every aspect of ...
(Date:2/19/2020)... SAN ANTONIO (PRWEB) , ... February 19, 2020 ... ... medical device and implant manufacturer, will highlight its growing product portfolio for lower ... February 18-22 at the Henry B. Gonzalez Convention Center. The Trigon® Ti Stand-Alone ...
(Date:2/15/2020)... ... 14, 2020 , ... UMF Corporation , a manufacturer ... a member of Prisma Health, providing a comprehensive PCPLUS program in ... to cut its monthly laundry management costs in half, support infection prevention, decrease ...
(Date:2/14/2020)... ... February 14, 2020 , ... Cloudticity announced today ... the company’s support for healthcare organizations using Amazon Web Services (AWS). , “Our ... or experience to do so,” explained Cloudticity Founder & CEO, Gerry Miller. “In ...
Breaking Medicine News(10 mins):